

APOLLO HOSPITALS ENTERPRISE LIMITED

CIN : L85110TN1979PLC008035



14th September 2020

The Secretary,
Bombay Stock Exchange Ltd (BSE)
Phiroze Jheejheebhoy Towers,
Dalal Street,
Mumbai - 400 001.

Scrip Code - 508869
ISIN INE437A01024

The Secretary,
National Stock Exchange,
Exchange Plaza, 5th Floor
Plot No.C/1, 'G' Block
Bandra - Kurla Complex
Bandra (E)
Mumbai - 400 051.

Scrip Code-
APOLLOHOSP
ISIN INE437A01024

The Manager
The National Stock
Exchange,
Wholesale Debt Market
Exchange Plaza, 5th Floor
Plot No.C/1, 'G' Block
Bandra - Kurla Complex
Bandra (E)
Mumbai - 400 051.
ISIN INE437A07062,
INE437A07070,
INE437A07088 &
INE437A07093

Dear Sir,

Sub: Decisions at the Board Meeting held on 14th September 2020

Further to our letters dated 30th June 2020 and 1st September 2020, the Board of Directors at the meeting held on 14th September 2020 have approved the unaudited financial results of the Company for the quarter ended 30th June 2020.

As required by the provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, (LODR) we enclose/furnish the following particulars.

Financial Results

1. Unaudited financial results (both standalone and consolidated) of the Company for the quarter ended 30th June 2020, which have been subjected to Limited Review by the Statutory Auditors of the Company - as Annexure I.
2. Copy of the Limited Review Report of the Statutory Auditors for the corresponding period.
3. The financial results will also be published in the newspapers, in the format prescribed under Regulation 47 of the Listing Regulations.
4. The said documents are being posted on the website of the Company i.e., www.apollohospitals.com.

IS/ISO 9001:2000


Regd. Office :
19, Bishop Gardens,
Raja Annamalaipuram,
Chennai - 600 028.

General Office :
"Ali Towers", III Floor,
#55, Greams Road,
Chennai - 600 006.

Tel : 044 - 28290956 / 3896 / 6681
Telefax : 044 - 2829 0956
Email : apolloshares@vsnl.net
Website: www.apollohospitals.com

APOLLO HOSPITALS ENTERPRISE LIMITED

CIN : L85110TN1979PLC008035



Schedule of Conference Call

Pursuant to Regulation 30 and 46 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that a conference call for the analysts/investors is scheduled to be held on Tuesday, 15th September 2020 at 2.00 p.m. to discuss the financial results for the quarter ended 30th June 2020.

The meeting of the Board of Directors commenced at 4.00 p.m. and concluded atp.m. 05:35

Please take note of the above in your records.

Thanking you,

Yours faithfully,
For APOLLO HOSPITALS ENTERPRISE LIMITED

S.M. KRISHNAN
VICE PRESIDENT - FINANCE
AND COMPANY SECRETARY

CC : The Secretary,
Luxembourg Stock Exchange,
B.P. 165,
L-2011 Luxembourg.

Securities and Exchange
Commission
Division of Corporation Finance
Office of International Corporate
Finance

Ref : ISIN US0376081065 - Rule 144a GDR
ISIN US0376082055 - Reg. S GDR

450 Fifth Street, N.W.
Washington, D.C
20549-0302
File No. 82-34893

IS/ISO 9001:2000

Regd. Office :
19, Bishop Gardens,
Raja Annamalaipuram,
Chennai - 600 028.

General Office :
"Ali Towers", III Floor,
#55, Greams Road,
Chennai - 600 006.

Tel : 044 - 28290956 / 3896 / 6681
Telefax : 044 - 2829 0956
Email : apolloshares@vsnl.net
Website: www.apollohospitals.com

Apollo Hospitals Enterprise Limited

Corporate Identity Number : L85110TN1979PLC008035

Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu

Tel No. 44-28290956 , Fax+ 91-44-282 90956, Email : investor.relations@apollohospitals.com

Website: www.apollohospitals.com

1. Statement of Unaudited Standalone Financial Results for the three months ended June 30, 2020

(Rs. in lakhs)

Particulars	Three months ended 30/06/2020	Preceding three months ended 31/03/2020	Corresponding three months ended 30/06/2019	Previous year ended 31/03/2020
	Unaudited	Refer Note 2	Unaudited	Audited
1 Income				
(a) Revenue from Operations	1,96,152	2,57,215	2,22,920	9,79,443
(b) Other Income	169	(77)	474	1,091
Total Income	1,96,321	2,57,138	2,23,394	9,80,534
2 Expenses				
(a) Cost of Materials Consumed	23,599	37,180	36,470	1,53,212
(b) Purchase of Stock-in-Trade	1,06,774	1,03,435	82,643	3,75,419
(c) Changes in inventories of stock-in-trade	(13,345)	(1,058)	(2,803)	(10,433)
(d) Employee Benefits Expense	37,678	39,295	35,284	1,51,918
(e) Finance Costs	10,262	10,729	9,991	42,588
(f) Depreciation and amortisation expense	12,644	12,905	10,981	48,226
(g) Other Expenses	37,301	43,529	38,746	1,67,803
Total Expenses	2,14,913	2,46,015	2,11,312	9,28,733
3 Profit / (Loss) before exceptional item and tax (1) - (2)	(18,592)	11,123	12,082	51,801
4 Exceptional Item	-	16,435	-	16,435
5 Profit / (Loss) before tax (3) - (4)	(18,592)	27,558	12,082	68,236
6 Tax Expenses				
Current Tax**	736	3,248	5,722	11,824
Deferred Tax**	(4,417)	3,748	(1,571)	9,387
7 Profit / (Loss) for the period (5) - (6)	(14,911)	20,562	7,931	47,025
8 Other Comprehensive Income				
Items that will not be reclassified to Profit and Loss				
Remeasurement gains / (losses) on defined benefit plan	(247)	78	207	115
-Tax on above	86	(27)	(72)	(40)
Total Other Comprehensive Income/ (Loss)	(161)	51	135	75
9 Total Comprehensive Income for the period / year (after tax) (7) + (8)	(15,072)	20,613	8,066	47,100
10 Paid-up equity share capital (Face value Rs.5/- per share)				6,956
11 Reserves (excluding Revaluation Reserves)				3,91,897
12 Net Worth (Refer footnote 1)				3,85,570
13 Earnings per equity share of Rs.5/- each				
Basic and Diluted EPS before extraordinary items for the period (Rs.)	*(10.72)	*14.78	*5.70	33.80
Basic and Diluted EPS after extraordinary items for the period (Rs.)	*(10.72)	*14.78	*5.70	33.80
Additional Information :-				
Earnings before finance costs, tax, depreciation and amortization, exceptional items (EBITDA) (Refer footnote 2)	4,145	51,270	32,580	1,57,959

*Not annualised

** Current tax and deferred tax expense for the three months ended June 30, 2020 includes tax of prior year amounting to Rs.2,169 lakhs.

Foot Notes:

1 Networth = Equity Share Capital + Other Equity excluding Capital Reserves, Capital Redemption Reserve and Debenture Redemption Reserve

For APOLLO HOSPITALS ENTERPRISE LTD.

Suneeta Reddy
Suneeta Reddy
Managing Director


Apollo Hospitals Enterprise Limited

Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai-28, Tamil Nadu

2. Segment wise Revenue, Results, Segment Assets and Segment Liabilities

(Rs. In lakhs)

Particulars	Three months ended 30/06/2020	Preceeding Three months ended 31/03/2020	Corresponding Three months ended 30/06/2019	Previous year ended 31/03/2020
	Unaudited	Refer Note 2	Unaudited	Audited
1. Segment Revenue				
Total Income from operations, Net				
a) Healthcare Services	68,243	1,21,377	1,17,258	4,97,466
b) Pharmacy	1,27,915	1,35,853	1,05,684	4,82,064
SUB - TOTAL	1,96,158	2,57,230	2,22,942	9,79,530
Less : Intersegmental Revenue	6	16	22	88
Income from Operations	1,96,152	2,57,214	2,22,920	9,79,442
2. Segment Results				
a) Healthcare Services	(16,695)	13,351	15,760	64,280
b) Pharmacy	8,196	8,576	5,839	29,017
SUB - TOTAL	(8,499)	21,927	21,599	93,297
Less : (i) Finance Cost	10,262	10,729	9,991	42,588
Add: (ii) Other un-allocable income, (net of expenditure)	169	(77)	474	1,091
Add: (iii) Exceptional item	-	16,435	-	16,435
Profit Before Tax	(18,592)	27,556	12,082	68,235
3. Capital employed				
Segment assets-Segment liabilities				
a) Healthcare Services *				
Segment Assets	6,78,756	6,76,963	6,57,178	6,76,963
Segment Liabilities	(1,63,684)	(1,55,148)	(1,49,448)	(1,55,148)
b) Pharmacy				
Segment Assets	2,10,960	2,05,500	1,77,970	2,05,500
Segment Liabilities	(1,16,370)	(1,12,755)	(94,660)	(1,12,755)
c) Unallocated				
Segment Assets	1,32,716	1,31,978	1,32,973	1,31,978
Segment Liabilities	(3,58,598)	(3,47,684)	(3,51,740)	(3,47,684)
Total	3,83,780	3,98,854	3,72,273	3,98,854
* Includes segment assets in various hospital projects under construction and intangible assets under development	20,989	22,653	81,576	22,653

For APOLLO HOSPITALS ENTERPRISE LTD.

 Sunesta Reddy
 Managing Director

NOTES:

1. The unaudited standalone financial results of Apollo Hospitals Enterprise Limited ("the Company") for the three months ended June 30, 2020 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on September 14, 2020 and have been subjected to limited review by the statutory auditors.
2. The standalone financial results for the three months ended March 31, 2020 are the balancing figures between the audited figures in respect of the full financial year and the unaudited year to date figures for the period ended December 31, 2019 which were subject to limited review.
3. The listed non-convertible debentures of the Company aggregating Rs. 50,000 lakhs as on June 30, 2020 are secured by way of first charge on the Company's properties and the asset cover thereof exceeds hundred percent of the principal amount of the said debentures.
4. Pursuant to the Scheme of Arrangement ('the Scheme'), duly sanctioned by the National Company Law Tribunal (NCLT) vide order dated August 3, 2020, with effect from April 1, 2019 ('Appointed date'), the front-end retail pharmacy included in the standalone pharmacy segment is transferred to Apollo Pharmacies Limited ("APL"), a wholly owned subsidiary of Apollo Medicals Private Limited (AMPL) for an overall cash consideration of Rs.52,780 lakhs. In accordance with Section 230 of the Companies Act, the Company filed the NCLT order with the Ministry of Company Affairs (Registrar of Companies) on September 1, 2020. Consequent to the filing, the Scheme became effective from September 1, 2020 ('effective date').

As per the Scheme, the Company shall account the transfer of assets and liabilities pertaining to the front-end retail pharmacy upon the Scheme becoming effective. Consequently, no impact of the aforesaid transfer have been given effect in the above results. The front-end retail pharmacy does not constitute a separate component under Ind AS 105 Non-current Assets Held for Sale and Discontinued Operations and represents a portion in the standalone pharmacy segment. Consequently, the transfer of front-end retail pharmacy has not been presented as a discontinued operations.

The Company holds 25.5% of the equity shares in AMPL as on the effective date.

5. The Board of Directors approved at its meeting held on February 13, 2020 the proposal for merger of the following wholly owned subsidiary companies with the Company.
 - a. Apollo Home Healthcare (India) Limited and
 - b. Western Hospitals Corporation Private Limited

The Company is in the process of submitting the requisite applications with NCLT seeking dispensing of convening shareholders/creditors meetings of the Company.

6. The Management has considered the possible effects if any that may result from the pandemic relating to COVID-19 on recoverability of receivables, Property, plant & equipment including Capital work in progress and certain investments. The Company has considered internal and external information up to the date of approval of these financial results. Based on the current indicators of future

For APOLLO HOSPITALS ENTERPRISE LTD.


Suneeta Reddy
Managing Director

economic conditions, the Company expects to recover the carrying amount of these assets. The actual outcome of these assumptions and estimates may vary in future due to the impact of the pandemic. The Company will continue to monitor any material changes to future economic conditions and the consequent impact on its business, if any, and any significant impact of these changes would be recognized in the financial results as and when these material changes to economic conditions arise.

7. The aforesaid financial results are also available on the Company's website (www.apollohospitals.com).

For APOLLO HOSPITALS ENTERPRISE LIMITED

Place: Chennai
Date: September 14, 2020

Dr. Prathap C Reddy
Executive Chairman

For APOLLO HOSPITALS ENTERPRISE LTD.


Suneeta Reddy
Managing Director

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF APOLLO HOSPITALS ENTERPRISE LIMITED

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **APOLLO HOSPITALS ENTERPRISE LIMITED** ("the Company"), for the three months ended June 30, 2020 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Deloitte Haskins & Sells LLP

5. We draw attention to Note 6 to the financial results, which describes Management's assessment of the impact of COVID -19 pandemic on significant uncertainties involved in developing some of the estimates involved in preparation of the financial results including recoverability of receivables, Property, plant & equipment including Capital work in progress and certain investments. Based on information available as of this date, Management believes that no further adjustments are required to the financial results. However, in view of the highly uncertain economic environment, a definitive assessment of the impact is highly dependent upon circumstances as they evolve in future and the actual results may differ from those estimated as at the date of approval of these financial results.

Our conclusion on the Statement is not modified in respect of this matter.

For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)

Digitally signed by Vikas
Bagaria
Date: 2020.09.14 16:10:18
+05'30'

Vikas Bagaria
Partner
(Membership No. 060408)

Place: Bengaluru
Date: September 14, 2020

1. Statement of Consolidated Financial Results for the three months ended June 30, 2020

(Rs. in lakhs)

Particulars	Three months ended 30/06/2020	Preceding three months ended 31/03/2020	Corresponding three months ended 30/06/2019	Previous year ended 31/03/2020
	Unaudited	Refer Note 2	Unaudited	Audited
1 Income				
(a) Revenue from Operations	2,17,150	2,92,243	2,57,189	11,24,680
(b) Other Income	772	395	986	2,697
Total Income	2,17,922	2,92,638	2,58,175	11,27,377
2 Expenses				
(a) Cost of Materials Consumed	27,681	44,102	42,872	1,80,923
(b) Purchases of stock-in-trade	1,07,325	1,04,406	83,735	3,79,667
(c) Changes in inventories of stock-in-trade	(13,253)	(1,400)	(2,831)	(10,703)
(d) Employee Benefits Expense	44,864	47,550	43,341	1,85,292
(e) Finance Costs	12,739	13,523	12,577	53,277
(f) Depreciation and amortisation expense	16,018	16,386	14,401	61,969
(g) Other Expenses	46,985	59,578	53,700	2,30,772
Total Expenses	2,42,359	2,84,145	2,47,795	10,81,197
3 Profit / (Loss) before share of profit / (loss) in associates / joint ventures and exceptional item (1) - (2)	(24,437)	8,493	10,380	46,180
4 Share of profit/ (loss) of associates / joint ventures	(2,263)	41	(940)	(311)
5 Profit / (Loss) before exceptional item and tax (3) + (4)	(26,700)	8,534	9,440	45,869
6 Exceptional Item	-	19,830	-	19,830
7 Profit / (Loss) before tax (5) + (6)	(26,700)	28,364	9,440	65,699
8 Tax Expenses				
Current Tax	828	3,151	6,085	12,720
Deferred Tax	(4,904)	4,253	(1,560)	9,799
9 Profit / (Loss) for the year (7) - (8)	(22,624)	20,960	4,915	43,180
10 Other Comprehensive Income / (Expense)				
Items that will not be reclassified to Profit or Loss				
Remeasurement gains / (losses) on defined benefit plan	(240)	607	211	(126)
Equity instruments through other comprehensive income	-	(11)	-	(11)
Tax on above	84	(152)	(72)	77
Total Other Comprehensive Income / (Expense)	(156)	444	139	(60)
11 Total Comprehensive Income / (Expense) for the year (after tax) (9) + (10)	(22,780)	21,404	5,054	43,120
Profit / (Loss) for the year attributable to:				
Owners of the parent	(20,819)	21,936	5,720	45,494
Non-controlling interest	(1,805)	(976)	(805)	(2,314)
Other Comprehensive Income / (Expense) for the year attributable to:				
Owners of the parent	(156)	255	139	(56)
Non-controlling interest	-	189	-	(4)
Total Comprehensive Income / (Expense) for the year attributable to:				
Owners of the parent	(20,975)	22,191	5,859	45,438
Non-controlling interest	(1,805)	(787)	(805)	(2,318)
12 Paid-up equity share capital (Face value Rs.5/- per share)				6,956
Reserves (excluding Revaluation Reserves)				3,26,209
13 Earnings per equity share of Rs.5/- each				
Basic and Diluted EPS before extraordinary items for the period (Rs.)	*(14.97)	*15.77	*4.11	32.70
Basic and Diluted EPS after extraordinary items for the period (Rs.)	*(14.97)	*15.77	*4.11	32.70

*Not annualised

** Current tax and deferred tax expense for the three months ended June 30, 2020 includes tax of prior year amounting to Rs.2,169 lakhs.

For APOLLO HOSPITALS ENTERPRISE LTD.

Suneeta Reddy
 Managing Director

Apollo Hospitals Enterprise Limited

Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai-28, Tamil Nadu
Consolidated Segment wise Revenue, Results, Segment Assets and Segment Liabilities

(Rs. in lakhs)

Particulars	Three months ended 30/06/2020	Preceeding three months ended 31/03/2020	Corresponding three months ended 30/06/2019	Current Year ended 31/03/2020
	Unaudited	Refer Note 2	Unaudited	Audited
1. Segment Revenue				
a) Healthcare Services	79,527	1,40,122	1,35,855	5,75,036
b) Pharmacy	1,27,915	1,35,853	1,05,684	4,82,064
c) Clinics	10,243	16,733	16,220	69,636
d) Others	100	110	108	438
SUB - TOTAL	2,17,785	2,92,818	2,57,867	11,27,174
Less : Intersegmental Revenue	635	575	678	2,494
Income from Operations	2,17,150	2,92,243	2,57,189	11,24,680
2. Segment Results				
a) Healthcare Services	(18,133)	13,776	17,321	70,244
b) Pharmacy	8,196	8,576	5,839	29,017
c) Clinics	(2,453)	(661)	(1,138)	(2,186)
d) Others	(80)	(70)	(51)	(315)
SUB - TOTAL	(12,471)	21,621	21,971	96,760
Less : (i) Finance Cost	12,739	13,523	12,577	53,277
Add: (ii) Other un-allocable expenditure	772	395	986	2,697
Add: (iii) Exceptional item	-	19,830	-	19,830
Profit Before Tax	(24,437)	28,323	10,380	66,010
3. Capital employed				
a) Healthcare Services *				
Segment Assets	7,60,769	7,60,180	7,42,719	7,60,180
Segment Liabilities	(2,37,602)	(2,28,645)	(2,23,700)	(2,28,645)
b) Pharmacy				
Segment Assets	2,10,960	2,05,500	1,77,970	2,05,500
Segment Liabilities	(1,16,370)	(1,12,755)	(94,660)	(1,12,755)
c) Clinics				
Segment Assets	80,898	82,317	80,948	82,317
Segment Liabilities	(62,829)	(63,665)	(59,987)	(63,665)
d) Others				
Segment Assets	4,699	4,774	4,822	4,774
Segment Liabilities	(1,875)	(1,948)	(1,779)	(1,948)
e) Unallocated				
Assets	73,136	81,078	77,696	81,078
Liabilities	(3,99,866)	(3,92,895)	(3,95,973)	(3,92,895)
Total	3,11,920	3,33,941	3,08,056	3,33,941
* Includes Capital employed in various hospital projects under construction and intangibles under development	21,483	23,561	81,576	23,561

For APOLLO HOSPITALS ENTERPRISE LTD.

Suneeta Reddy
Managing Director

NOTES:

1. The unaudited consolidated financial results of Apollo Hospitals Enterprise Limited ("the Group") and its subsidiaries (referred to as "Group") and its share of profit/loss of its associates and joint ventures, for the three months ended June 30, 2020 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on September 14, 2020 and have been subjected to limited review by the statutory auditors.
2. The consolidated financial results for the three months ended March 31, 2020 are the balancing figures between the audited figures in respect of the full financial year and the unaudited year to date figures for the period ended December 31, 2019 which were subject to limited review.
3. The listed non-convertible debentures of the Parent aggregating Rs. 50,000 lakhs as on June 30, 2020 are secured by way of first charge on the Company's properties and the asset cover thereof exceeds hundred percent of the principal amount of the said debentures.
4. Pursuant to the Scheme of Arrangement ('the Scheme'), duly sanctioned by the National Company Law Tribunal (NCLT) vide order dated August 3, 2020, with effect from April 1, 2019 ('Appointed date'), the front-end retail pharmacy included in the standalone pharmacy segment is transferred to Apollo Pharmacies Limited ("APL"), a wholly owned subsidiary of Apollo Medicals Private Limited (AMPL) for an overall cash consideration of Rs.52,780 lakhs. In accordance with Section 230 of the Companies Act, the Company filed the NCLT order with the Ministry of Company Affairs (Registrar of Companies) on September 1, 2020. Consequent to the filing, the Scheme became effective from September 1, 2020 ('effective date').

As per the Scheme, the Group shall account the transfer of assets and liabilities pertaining to the front-end retail pharmacy upon the Scheme becoming effective. Consequently, no impact of the aforesaid transfer have been given effect in the above results. The front-end retail pharmacy does not constitute a separate component under Ind AS 105 Non-current Assets Held for Sale and Discontinued Operations and represents a portion in the standalone pharmacy segment. Consequently, the transfer of front-end retail pharmacy has not been presented as a discontinued operations.


The Group holds 25.5% of the equity shares in AMPL as on the effective date.

5. The Board of Directors approved at its meeting held on February 13, 2020 the proposal for merger of the following wholly owned subsidiary companies with the Company.
 - a. Apollo Home Healthcare (India) Limited and
 - b. Western Hospitals Corporation Private Limited

The Parent is in the process of submitting the requisite applications with NCLT seeking dispensing of convening shareholders/creditors meetings of the Company.

6. The Management has considered the possible effects if any that may result from the pandemic relating to COVID-19 on recoverability of receivables, Property, plant & equipment including Capital work in progress and certain investments. The Group

For APOLLO HOSPITALS ENTERPRISE LTD.


Suneeta Reddy
Managing Director

has considered internal and external information up to the date of approval of these financial results. Based on the current indicators of future economic conditions, the Group expects to recover the carrying amount of these assets. The actual outcome of these assumptions and estimates may vary in future due to the impact of the pandemic. The Group will continue to monitor any material changes to future economic conditions and the consequent impact on its business, if any, and any significant impact of these changes would be recognized in the financial results as and when these material changes to economic conditions arise.

7. The proceedings initiated against Imperial Hospitals and Research Centre Limited, a subsidiary company, by the Government of Karnataka alleging, non-compliance of certain conditions associated with the allotment of land, has been stayed by the Honourable High Court of Karnataka on April 27, 2018. Based on legal opinion, the management is of the opinion that it has adequate grounds to demonstrate compliance with applicable conditions and therefore the proceedings are not sustainable. There have been no further developments during this quarter.
8. The aforesaid financial results are also available on the Company's website (www.apollohospitals.com).

For APOLLO HOSPITALS ENTERPRISE LIMITED

Place: Chennai
Date: September 14, 2020

Dr. Prathap C Reddy
Executive Chairman

For APOLLO HOSPITALS ENTERPRISE LTD


Suneeta Reddy
Managing Director

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF APOLLO HOSPITALS ENTERPRISE LIMITED

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **APOLLO HOSPITALS ENTERPRISE LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit after tax and total comprehensive income for the quarter ended June 30, 2020 of an associate and its share of the net loss after tax and total comprehensive loss (net) of seven joint ventures and associates for the quarter ended June 30, 2020, ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:

Name of the Company	Relationship
Apollo Hospitals Enterprise Limited	Parent
Apollo Home Healthcare (India) Limited	Subsidiary
Apollo Home Healthcare Limited	Subsidiary
AB Medical Centres Limited	Subsidiary
Samudra Health Care Enterprises Limited	Subsidiary
Imperial Hospitals & Research Centre Limited	Subsidiary
Apollo Hospitals (UK) Limited	Subsidiary
Apollo Health and Lifestyle Limited (AHLL)	Subsidiary
Alliance Dental Care Limited	Subsidiary of AHLL
Apollo Dialysis Private Limited	Subsidiary of AHLL
Apollo Sugar Clinics Limited	Subsidiary of AHLL

Deloitte Haskins & Sells LLP

Apollo Specialty Hospitals Private Limited	Subsidiary of AHLL
AHLL Diagnostics Limited	Subsidiary of AHLL
AHLL Risk Management Private Limited	Subsidiary of AHLL
Apollo Bangalore Cradle Limited	Stepdown Subsidiary of AHLL
Kshema Healthcare Private Limited	Stepdown Subsidiary of AHLL
Apollo Nellore Hospital Limited	Subsidiary
Sapien Bio-sciences Private Limited	Subsidiary
Apollo Hospitals International Limited (AHIL)	Subsidiary
Apollo-Amrish Oncology Services Private Limited	Associate of AHIL
Apollo CVHF Limited	Subsidiary of AHIL
Western Hospitals Corporation Limited	Subsidiary
Apollo Lavasa Health Corporation Limited	Subsidiary
Apollo Rajshree Hospital private Limited	Subsidiary
Future Parking Private Limited	Subsidiary
Total Health	Subsidiary
Apollo Hospitals Singapore Pte Limited	Subsidiary
Assam Hospitals Limited	Subsidiary
Apollo Medical Private Limited (AMPL)	Subsidiary
Apollo Pharmacy Limited	Subsidiary of AMPL
Apollo Gleneagles Hospitals Limited	Joint venture
Apollo Gleneagles PET-CT private Limited	Joint venture
ApoKos Rehab Private limited	Joint venture
Medics International Lifesciences Limited	Joint Venture
Family Health Plan Insurance (TPA) Limited	Associate
Indraprastha Medical Corporation Limited	Associate
Stemcyte India Therapeutics Private Limited	Associate

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We draw attention to Note 7 to the Statement in respect of proceedings initiated against the subsidiary, Imperial Hospitals & Research Centre Limited, by the Government of Karnataka, as reported by the other auditors of the said subsidiary company. Our conclusion on the Statement is not modified in respect of this matter.
7. We draw your attention to Note 6 to the Statement, which describes Management's assessment of the impact of COVID -19 pandemic on significant uncertainties involved in developing some of the estimates involved in preparation of the financial results including recoverability of receivables, Property, plant & equipment including Capital work in progress and certain investments. Based on information available as of this date, Management believes that no further adjustments are required to the financial results. However, in view of the highly uncertain economic environment, a definitive assessment of the impact is highly dependent upon circumstances as they evolve in future and the actual results may differ from those estimated as at the date of approval of these financial results. Our conclusion on the Statement is not modified in respect of this matter.

Deloitte Haskins & Sells LLP

8. We did not review the interim financial results of 20 subsidiaries included in the consolidated unaudited financial results, whose interim financial results reflect total revenues of Rs. 14,111 lakhs for the three months ended June 30, 2020, total net loss after tax of Rs. 2,050 lakhs for the three months ended June 30, 2020 and total comprehensive loss of Rs. 2,050 lakhs for the three months ended June 30, 2020, as considered in the Statement. The consolidated unaudited financial results also includes the Group's share of loss after tax of 480 for the three months ended June 30, 2020 and total comprehensive loss Rs. 475 lakhs for the three months ended June 30, 2020, as considered in the Statement, in respect of 1 joint ventures and 2 associates, whose interim financial results have not been reviewed by us. These interim financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, joint ventures and associates, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of these matters.

9. The consolidated unaudited financial results includes the interim financial information of 6 subsidiaries which have not been reviewed / audited by their auditors, whose interim total revenue of Rs. Nil for the three months ended June 30, 2020, total profit after tax of Rs. 8 lakhs for the three months ended June 30, 2020 and total comprehensive income Rs. 8 lakhs for the three months ended June 30, 2020, as considered in the Statement. The consolidated unaudited financial results also includes the Group's share of loss after tax of Rs. 74 lakhs for the three months ended June 30, 2020 and total comprehensive loss of Rs. 74 lakhs for the three months ended June 30, 2020, as considered in the Statement, in respect of 2 joint venture and 2 associate, based on its interim financial information which have not been reviewed / audited by their auditors. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group.

Our Conclusion on the Statement is not modified in respect of our reliance on the interim financial information certified by the Management.

For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)

Digitally signed by Vikas
Bagaria
Date: 2020.09.14 16:41:38
+05'30'

Vikas Bagaria
Partner
(Membership No. 060408)

Place: Bengaluru
Date: September 14, 2020